Universe Pharmaceuticals (UPC) Competitors $3.43 -0.14 (-3.92%) As of 08/21/2025 01:17 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock UPC vs. CLRB, CYCN, MBIO, EVOK, APM, ARTL, GNPX, BCLI, ALZN, and SBFMShould you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Cellectar Biosciences (CLRB), Cyclerion Therapeutics (CYCN), Mustang Bio (MBIO), Evoke Pharma (EVOK), Aptorum Group (APM), Artelo Biosciences (ARTL), GENPREX (GNPX), Brainstorm Cell Therapeutics (BCLI), Alzamend Neuro (ALZN), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical products" industry. Universe Pharmaceuticals vs. Its Competitors Cellectar Biosciences Cyclerion Therapeutics Mustang Bio Evoke Pharma Aptorum Group Artelo Biosciences GENPREX Brainstorm Cell Therapeutics Alzamend Neuro Sunshine Biopharma Cellectar Biosciences (NASDAQ:CLRB) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Is CLRB or UPC more profitable? Universe Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A -486.67% -150.57% Universe Pharmaceuticals N/A N/A N/A Do analysts recommend CLRB or UPC? Cellectar Biosciences currently has a consensus price target of $375.00, indicating a potential upside of 8,251.89%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectar Biosciences is more favorable than Universe Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Universe Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer CLRB or UPC? In the previous week, Cellectar Biosciences had 3 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for Cellectar Biosciences and 0 mentions for Universe Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 0.29 beat Universe Pharmaceuticals' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Overall Sentiment Cellectar Biosciences Neutral Universe Pharmaceuticals Neutral Do institutionals & insiders believe in CLRB or UPC? 16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 5.0% of Cellectar Biosciences shares are owned by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, CLRB or UPC? Cellectar Biosciences has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Which has stronger earnings and valuation, CLRB or UPC? Universe Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$44.58M-$19.91-0.23Universe Pharmaceuticals$23.02M0.08-$8.73MN/AN/A SummaryCellectar Biosciences and Universe Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Universe Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPC vs. The Competition Export to ExcelMetricUniverse PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.01M$2.53B$5.76B$9.60BDividend YieldN/A1.66%3.84%4.08%P/E RatioN/A22.4830.4025.20Price / Sales0.08730.63456.34115.68Price / CashN/A173.2237.1558.42Price / Book0.005.729.006.24Net Income-$8.73M$31.83M$3.26B$265.30M7 Day Performance-3.65%0.82%1.06%-1.13%1 Month Performance-1.44%3.71%4.31%-0.71%1 Year PerformanceN/A9.37%28.39%18.86% Universe Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPCUniverse Pharmaceuticals0.7471 of 5 stars$3.43-3.9%N/AN/A$2.01M$23.02M0.00220Gap DownCLRBCellectar Biosciences2.4304 of 5 stars$4.34-1.8%$375.00+8,540.6%-93.0%$7.86MN/A-0.2210Earnings ReportHigh Trading VolumeCYCNCyclerion Therapeutics2.4404 of 5 stars$2.36+1.3%N/A-17.9%$7.86M$2M-3.1930Positive NewsShort Interest ↓MBIOMustang Bio1.0313 of 5 stars$1.77-0.6%N/A-90.8%$7.75MN/A-0.02100Positive NewsGap DownEVOKEvoke Pharma0.426 of 5 stars$5.12-0.4%N/A+30.5%$7.64M$10.25M-2.004Earnings ReportGap DownAPMAptorum Group0.7236 of 5 stars$1.39-4.8%N/A+37.1%$7.43MN/A0.0030News CoverageTrading HaltedARTLArtelo Biosciences3.1173 of 5 stars$10.02-0.7%$24.00+139.5%+18.5%$7.06MN/A-0.535News CoverageAnalyst ForecastShort Interest ↓GNPXGENPREX1.5164 of 5 stars$0.21-1.8%N/A-79.6%$7.03MN/A0.0020Earnings ReportShort Interest ↑BCLIBrainstorm Cell Therapeutics2.5435 of 5 stars$0.63+3.6%N/A-88.4%$6.90MN/A-0.1940Short Interest ↓ALZNAlzamend Neuro2.5512 of 5 stars$2.38-2.1%$180.00+7,463.0%-94.0%$6.88MN/A0.004Analyst ForecastShort Interest ↑Gap DownSBFMSunshine Biopharma2.1526 of 5 stars$1.49-1.3%$15.00+906.8%-52.6%$6.79M$34.87M-0.013 Related Companies and Tools Related Companies Cellectar Biosciences Alternatives Cyclerion Therapeutics Alternatives Mustang Bio Alternatives Evoke Pharma Alternatives Aptorum Group Alternatives Artelo Biosciences Alternatives GENPREX Alternatives Brainstorm Cell Therapeutics Alternatives Alzamend Neuro Alternatives Sunshine Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPC) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Universe Pharmaceuticals INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Universe Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access